Filter
Exclude
Time range
-
Near
editasmed
Thank you to everyone who joined us last week at Cell & Gene Therapy World Asia 2026. It was a pleasure connecting with colleagues from across the cell and gene therapy community and sharing insights on the value of early CMC integration. #CGTAsia2026 #CGTWA2026 #CMC #biotech
Pratish Bhanushali retweeted
TradingMarvel
Chart of this multibagger potential looking good Sl -15 Brawn Biotech Others chart shared on free telegram
🚀 𝗦𝗵𝗮𝗿𝗶𝗻𝗴 𝗠𝘆 𝗛𝗶𝗴𝗵-𝗖𝗼𝗻𝘃𝗶𝗰𝘁𝗶𝗼𝗻 #𝗣𝗲𝗻𝗻𝘆𝗦𝘁𝗼𝗰𝗸𝘀 𝘄𝗶𝘁𝗵 #𝗠𝘂𝗹𝘁𝗶𝗯𝗮𝗴𝗴𝗲𝗿 𝗣𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹! 📈 𝗦𝘁𝗼𝗰𝗸𝘀 𝘁𝗼 𝗪𝗮𝘁𝗰𝗵: ➊ 𝗕𝗖𝗚 — ₹9.97 ➋ 𝗗𝗣𝗦𝗖 — ₹7.51 ➌ 𝗔𝗸𝘀𝗵 𝗢𝗽𝘁𝗶𝗳𝗶𝗯𝗿𝗲 — ₹6.60 ➍ 𝗚𝗼𝘆𝗮𝗹 𝗔𝗹𝘂𝗺𝗶𝗻𝗶𝘂𝗺 — ₹6.80 ➎ 𝗩𝗮𝗶𝘀𝗵𝗮𝗹𝗶 𝗣𝗵𝗮𝗿𝗺𝗮 — ₹7.31 ➏ 𝗕𝗿𝗮𝘄𝗻 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 — ₹19.75 ⚡ 𝗛𝗶𝗴𝗵 𝗥𝗶𝘀𝗸 • 𝗛𝗶𝗴𝗵 𝗥𝗲𝘄𝗮𝗿𝗱 ⏳ 𝗙𝗼𝗿 𝗟𝗼𝗻𝗴-𝗧𝗲𝗿𝗺 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗢𝗻𝗹𝘆. Overall Ranking*️⃣ 🥇 Vaishali Pharma — 7.5/10 🥈 DPSC — 6.5/10 🥉 Goyal Aluminium — 5.5/10 For high-risk multibagger portfolio, Vaishali Pharma and Goyal Aluminium appear to have the strongest balance of fundamentals and upside potential among this group.
8
30
261
31,677
MehdiShahp
Structural Investment Themes for the Next Decade 1. Life Sciences & Longevity Aging populations create a structural, non-cyclical demand driver for healthcare innovation. GLP-1 therapies, oncology, cell and gene therapy, and longevity biotech are reaching commercial scale after years of scientific progress, expanding the addressable market over time. 2. Power & Energy Infrastructure The defining bottleneck of the decade. AI compute, electrification, and industrial growth are overwhelming grid capacity and power delivery. Investment in transmission, grid-scale storage, data-centre power, and energy security is supported by both commercial demand and sovereign priorities. 3. Automation & Intelligent Systems Structural labour shortages are making robotics, autonomous logistics, and AI-powered manufacturing operational necessities rather than optional upgrades. Advances in AI and rising defence spending broaden the opportunity while adding a counter-cyclical element. 4. AI & Digital Infrastructure AI growth depends on physical infrastructure. The highest-conviction opportunities lie in the enabling layers—compute, networking, liquid cooling, and power delivery—rather than more richly valued semiconductor companies. 5. Circular Economy & Advanced Materials Regulation, particularly in Europe, is creating durable, policy-backed demand for recycled materials and sustainable manufacturing. Advanced recycling, waste-to-value technologies, and sustainable packaging offer steadier growth than consumer-driven sustainability themes. 6. Housing & Built Environment Chronic housing shortages across developed markets require more productive construction. Modular building, digital platforms, and industrialised construction offer scalable solutions, though adoption remains gradual due to planning, financing, and regulatory constraints. 7. Food Security & AgTech Climate volatility, population growth, and supply-chain risks make food security a long-term strategic priority. Precision agriculture, resilient farming systems, and alternative proteins offer significant potential but require patient capital due to slower adoption. Invest where long-term demand is inevitable, capital intensity creates barriers to entry, and structural tailwinds can compound value over many years. #Housing #MMC #Infra #Circular-economy #Peptides #Longevity #Energy
2
Jake retweeted
SRxTrades
$XBI Absolutely incredible breakout in biotech.. Just riding the 8 Day EMA higher One positive headline away from an explosive move into new all time highs
$XBI Biotech stocks continue to push higher out of this weekly base This sector is likely going to continue to show strength into year and and run into new highs
12
10
72
24,200
Indicfederr0d
Knowledge City is a great start. Tamil Nadu should aim to become India's deep-tech capital by attracting the world's top universities, creating dedicated AI, quantum, semiconductor, biotech and robotics districts, funding university-industry R&D, offering plug-and-play research parks, attracting global faculty, simplifying visas for researchers, and incentivizing multinational companies to establish global R&D centres. Research should move seamlessly from labs to startups to manufacturing. That's how Singapore and Taiwan built globally competitive innovation ecosystems. 📸:@hosurupdates
7
gbusequel
Replying to @DJones88888888
Yes — removing federal transfers to Ottawa and shedding many overlapping federal regulations would unlock significant fiscal headroom and policy flexibility for Alberta. Alberta already acts as a major net contributor to Canadian federal finances (tens of billions over recent decades, with annual net outflows often in the $10–15 billion range in stronger years). Keeping those funds domestically, combined with a Monaco-style low/no personal income tax model and its vast resources, could supercharge growth across multiple sectors.121 Fiscal Freedom: More Money Stays Home •No more net transfers — Billions currently sent federally could directly fund provincial priorities (or tax cuts). This includes savings on overlapping bureaucracy, equalization-style programs, and federal program overhead. •Resource revenues amplified — Royalties from oil sands (world-scale reserves), natural gas (recently revised much higher), and other resources stay fully within Alberta and feed an expanded sovereign wealth fund (building on the existing ~$32 billion Heritage Savings Trust Fund). This creates a self-sustaining revenue engine for services without heavy reliance on broad-based taxes.128 •Low-tax magnet effect — Zero or near-zero personal income tax (building on Alberta’s already competitive rates and lack of PST) attracts high-net-worth residents, entrepreneurs, retirees, and corporations. Revenue shifts to consumption taxes, resource fees, real estate, tourism levies, and targeted business charges — classic Monaco playbook. Sector-by-Sector Mecca Potential Business & Finance
Calgary could evolve into a global energy finance, trading, and wealth management hub. Low taxes regulatory agility attract head offices, investment funds, and startups. Reduced federal red tape on banking, securities, and cross-border flows speeds innovation. Energy transition tech (carbon capture, hydrogen, critical minerals) gets fast-tracked. Healthcare
With retained funds and lighter federal constraints, Alberta could pioneer a competitive, patient-centered system — mix of public baseline private options, innovation incentives (e.g., medical tourism, research hubs, specialized clinics), and faster approvals for treatments/devices. Attract world-class doctors and patients seeking high-quality, timely care in a lower-tax environment. Farming & Agriculture
Alberta is already a powerhouse in grains, canola, beef, and more. Independence means streamlined trade deals, reduced federal marketing/inspection overlaps, and policies tailored to local conditions (water management, innovation in precision ag, exports). Tax advantages draw agribusiness investment and value-added processing. Education
Fund top-tier universities and vocational training with resource wealth. Attract international students and faculty with affordable tuition (for locals), low living costs relative to outcomes, and research freedom. Become a destination for STEM, energy engineering, agriculture, and business programs — with lower taxes retaining graduates and entrepreneurs. Energy & Resources (Core Engine)
Unencumbered development of oil/gas/minerals (with environmental safeguards chosen locally) maximizes output and royalties. Faster permitting, pipeline/export infrastructure, and investment in responsible extraction/transition technologies. This funds everything else while creating high-wage jobs. Tourism, Real Estate & Lifestyle
Market the Rockies (Banff/Jasper), prairies, and urban amenities as a luxury destination. High-end resorts, adventure, events, and second homes for wealthy newcomers. Real estate development booms responsibly, generating fees and economic activity. Other Sectors (“etc.”) •Tech & Innovation — Low taxes research freedom draw AI, cleantech, and biotech. •Manufacturing & Logistics — Energy abundance trade autonomy. •Immigration & Talent — Tailored, needs-based policies to fill skills gaps without federal caps. Overall Vision & Outcomes
1
9
Ezequiel Mc Govern retweeted
dhurtado171045
La nota que copia Ravier dice: "SC Johnson, Pfizer y Sinergium Biotech ya anunciaron inversiones en el país". Todas empresas de EEUU, que no invierten en I D acá, nos venden sus desarrollos a precios de oligopolio. Es humillante y desastroso Ravier. ¿Qué piensa CILFA de esto?
La salud como motor estratégico del desarrollo argentino - por Mario Lugones | para @infobae Mayor inversión y apertura en la industria farmacéutica y biotecnológica posicionan a Argentina como referente internacional en salud. @Mariolugones_ar infobae.com/opinion/2026/05/…
1
5
8
348
sharonsdogs
华为昇腾 商业航天 存储涨价!四大主线引爆明日A股“硬核科技”行情 一、韬定律(华为昇腾生态) 核心驱动:华为韬定律V2推动先进封装技术落地,国产EDA工具突破关键瓶颈 潜在机会: 1. 概伦电子(688206):国内EDA龙头,深度绑定华为昇腾,14nm先进工艺覆盖度超90% 2. 华大九天(301269):唯一通过华为认证的国产EDA厂商,布局Chiplet设计工具链 3. 中电港(001287):英伟达Jetson系列独家代理商,AI算力硬件分销龙头(注:7月6日已涨停) 4. 长电科技(600584):国内封测龙头,为华为昇腾提供2.5D/3D先进封装服务 5. 通富微电(002156):AMD核心合作伙伴,3nm Chiplet量产良率超95%,间接进入英伟达CPO供应链 6. 华天科技(002185):车载芯片封装领军者,华为昇腾车载计算模块主力供应商 7. 晶方科技(603005):CIS芯片封装龙头,深度受益AI视觉传感器需求爆发 8. 航天电器(002025):华为昇腾服务器高速连接器核心供应商,订单排至2027Q1 9. 华丰科技(688629):服务器CPU Socket国产替代先锋,224G高速线模组批量交付 10. 伟测科技(688372):AI芯片测试设备龙头,与长电科技共建先进封装测试联合实验室 二、创新药(政策 出海双轮驱动) 核心驱动:国家药监局“30日审评通道”加速CGT药品落地,中国创新药License-out金额突破千亿 潜在机会: 1. 首药控股(688197):国产ALK抑制剂领军者,海外授权首付款超5亿美元 2. 药明康德(603259):CXO龙头,全球布局抵消地缘风险,AI辅助药物设计提速 3. 康龙化成(300759):实验室服务收入占比超60%,受益中小Biotech研发投入回暖 4. 凯莱英(002821):CDMO龙头,连续三年获辉瑞“全球最佳供应商”,产能利用率超90% 5. 泰格医药(300347):临床CRO龙头,全球多中心试验能力获FDA认可 6. 九洲药业(603456):多肽类药物CDMO领先者,与礼来、诺华签订5年框架协议 7. 博腾股份(300363):基因与细胞治疗CDMO新锐,2026年新增订单同比增180% 8. 昭衍新药(603127):实验动物供应垄断者,临床前安全性评价市占率超35% 三、商业航天(IPO热潮 发射窗口期) 核心驱动:蓝箭航天、中科宇航竞逐“商业航天第一股”,SpaceX市值锚定估值重构 潜在机会: 1. 盟升电子(688311):卫星通信载荷龙头,星链地面终端核心供应商 2. 中国卫通(601698):G60星座运营商,独享Ka频段稀缺资源 3. 中国卫星(600118):小卫星总装龙头,承担GW星座80%以上发射任务 4. 航天电子(600879):火箭控制系统核心供应商,受益长征十号乙首飞 5. 北斗星通(002151):卫星导航芯片龙头,车规级高精度定位模块量产 6. 上海瀚讯(300762):天通卫星通信系统供应商,军用市场占有率超60% 7. 派克新材(605123):航天级环形锻件龙头,长征系列火箭核心部件供应商 8. 广联航空(300900):复合材料机身段制造商,C919大飞机订单持续落地 四、存储芯片(涨价周期 国产替代) 核心驱动:三星DRAM三季度涨价20%,国内厂商锁量锁价锁定利润 潜在机会: 1. 江波龙(301308):存储模组龙头,上半年净利预增743倍,LTA长单保障供应 2. 佰维存储(688525):126亿长单锁定成本,企业级SSD市占率国内第一 3. 紫光国微(002049):特种DRAM垄断者,AI服务器内存接口芯片突破 4. 深科技(000021):存储封测龙头,与长鑫存储共建12英寸晶圆级封测产线 5. 东芯股份(688110):国产NAND Flash领军者,车规级产品通过AEC-Q100认证 6. 兆易创新(603986):NOR Flash全球第二,利基DRAM量价齐升 7. 利尔达(688656):物联网存储方案商,NB-IoT模组全球市占率超20% 8. 亚威股份(002559):存储芯片激光修复设备供应商,国产替代率超85% 明日策略: - 重点关注:通富微电(AI封装)、中电港(算力分销)、江波龙(存储涨价)、中国卫通(商业航天) - 风险提示:商业航天板块短期涨幅过高(昊志机电年内涨74%),存储芯片价格见顶风险 - 事件催化:华为昇腾WAIC 2026发布Atlas 950 SuperPoD(关注华丰科技、航天电器)
2
1
1
62
moleculexx
🌟 FRESH SIGNAL 🎯 $TENX · Phase 2 → Phase 3 MID-term · conviction 70/100 Entry $15.38–$15.53 → Target $19.32–$20.86 TENAX THERAPEUTICS, INC. (TENX) trades at $15.46, within a narrow range that suggests investors are weighing the company's current prospects. With a conviction score of 69.5/100, the stock has cleared initial hurdles, including a Stage-1 gate and a Stage-2 LLM scan. The clinical vector stands at 76/100, supported by 5 active trials in the ClinicalTrials registry, indicating progress in its therapeutic programs. The capital vector, at 63/100, reflects recent insider activity and material events disclosed in SEC filings. … ⚠ Not financial advice · @moleculexx #TENX #Tenax #TenaxTherapeutics #Phase3 #FDA #Catalyst #ScienceTwitter #SwingTrading #Biotech #Biopharma #BiotechStocks #Pharma #DrugDevelopment #ClinicalTrials #LifeSciences #Stocks #Investing #StockMarket #StocksToWatch #GrowthStocks
4
mmsacode
📅 6 يوليو 2026 🧬 $BLTE Belite Bio تعلن مشاركتها في ندوة افتراضية للمستثمرين. التأثير المحتمل: محايد ⚖️ مشاركة مؤتمرات المستثمرين مهمة للمتابعة، لكنها ليست محفزاً قوياً إلا إذا تضمنت بيانات أو تحديثات سريرية جديدة. #BLTE #Biotech #InvestorEvent
6
Cristina Sánchez retweeted
matthewherper
So last week I spoke to @AnthropicAI CEO @DarioAmodei about how AI could change biotech. I also got to speak to other Anthropic execs, large pharmaceutical CEOs, and GLP-1 pioneer @lotte_bjerre. Here's what I learned: The most convincing thing to me is that Amodei recognized the limitations of biotech in way he didn't in his 2024 essay, “Machines of Loving Grace.” He forecasts that someday AI will allow researchers to make a decade's worth of progress every year. He said he's "very specifically not saying we’re going to get all this crazy stuff by 2028 or something. There’s simply no way to do it." I asked Amodei why we should believe in this tech/biotech revolution when past ones have failed. Pharma execs listed every reason to be cautious -- and why they'd be happy with 40%, 10%, or 5% gains -- and the nightmare scenarios that could make it all worse. But Lotte said this: "I would say AI is not going to replace scientists. I’m not worried about that at all. But scientists who are not using AI are going to get replaced."
1
5
4
1,529
pash22
@matthewherper spoke to @AnthropicAI ’s CEO @DarioAmodei about how AI may affect biotech. Here’s what he learned: Even if the biggest claims about the technology are hype, it may still have an immediate impact statnews.com/2026/07/06/anth…
1
2
21
𝘾𝙝𝙖𝙢𝙞𝙣𝙎 retweeted
tfboys_rinda
3 ล้านคนแย่งบัตรคอนเสิร์ตไคบอส วิเดียวจบ! หมด! ณ.สถานีฉงชิ่ง วันที่ 18 19 กรกฎาคมนี้ ณ.Bloomage Biotech · Biohyalux ECM Arena #TFBOYS #KarryWang #Junkai #王俊凯 #คอนเสิร์ตไคบอส Cr. 王俊凯KarryWang工作室
1
24
22
786
EteMoon57994
Here are my picks for each theme, split into lower risk (1st) and higher risk (2nd): 🤖 Robotics & drones: $AMZN $ONDS 👨‍🔬 Biotech/AI crossover: $IBB $TEM 🧬 Genomics: $ARKG $PRME 🔌 Battery storage: $TSLA $FLNC 🔋 Next gen batteries: $QS $EOSE (both very high risk)
74
LVReddy73
₹800 crore investment lands in #KCR's #Gajwel constituency. Development speaks louder than politics. IT & Industries Minister D. Sridhar Babu inaugurated India's first Integrated #Oncology Manufacturing Facility, set up by #Ciro Pharma Pvt. Ltd with an investment of ₹800 crore at Biotech Park Phase-III, #Karakapatla, #Markook Mandal, #Siddipet district. Sridhar Babu said the #Congress government is determined to make #Telangana the country's benchmark for industrial growth. He also announced a special action plan to transform the #Zaheerabad #NIMZ into a world-class manufacturing hub. Sridhar Babu said #BRS spreading misinformation about #Revanth govt's flagship initiatives such as Bharat Future City and the #HILT Policy. He said Telangana's rapid industrial progress under Chief Minister A. Revanth Reddy over the last two-and-a-half years has left the opposition BRS and #BJP rattled, prompting them to resort to a campaign of false propaganda against Congress govt. Investment. Jobs. Manufacturing. Growth. That's the Telangana story, Sridhar Babu said. #Telangana #Investment #Pharma #IndustrialGrowth #RevanthReddy #SridharBabu #Congress #MakeInIndia #Gajwel #Siddipet
305
WIZYBIT2000
🧬 $MRK Merck's phase-transition cluster landed mixed — three oncology trials completed against one Alzheimer's termination. In a compressed week (late June into early July 2026), Merck Sharp & Dohme closed three separate Phase 2 and Phase 3 cancer studies: KEYNOTE-B99 in small-cell lung cancer, a hepatocellular carcinoma combination with Lenvatinib, and KEYVIBE-003 testing a Pembrolizumab/Vibostolimab coformulation in non-small-cell lung. The bladder-cancer trial EV-304 also crossed the finish line. Each completion opens the pathway to interim or final efficacy readouts — standard catalysts for the Pembrolizumab franchise. Against that backdrop, MK-1167-008, an Alzheimer's dementia study, was terminated, signaling a therapeutic setback in a program Merck had pursued parallel to its oncology fortress. The portfolio divergence arrived as corporate insiders executed net selling across four consecutive trading days, and Rep. Keith Alan Self (R-TX) filed a disclosure of a $15,000 sale in early July with a 536-day reporting lag — both signals carrying weak bearish lean. The termination and insider drift tempered the optimism from multiple trial completions, a common pattern when a biotech giant must balance wins in its core competency against portfolio pruning elsewhere. Full story: insider.wizybit.com/blog/pos…
th3_m0l3
$ZVRA is rare-disease optionality, not a core compounder. That distinction matters. Small position, binary-ish catalysts, clear reason to keep it away from comfort-sized allocation. Sizing 4%. #finx #biotech
9